Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACET NASDAQ:GNLX NASDAQ:LFCR NASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACETAdicet Bio$0.91-1.6%$0.76$0.45▼$1.54$77.32M1.621.88 million shs2.29 million shsGNLXGenelux$5.67+19.4%$3.82$1.99▼$5.89$179.42M-0.22136,522 shs368,482 shsLFCRLifecore Biomedical$6.63-3.5%$7.40$4.33▼$8.85$257.39M0.62215,235 shs270,006 shsVRCAVerrica Pharmaceuticals$4.30-2.7%$5.21$3.82▼$17.38$41.75M1.71598,801 shs190,316 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACETAdicet Bio-1.56%+10.42%+13.75%+21.97%-35.62%GNLXGenelux+19.37%+29.16%+54.50%+65.31%+116.41%LFCRLifecore Biomedical-3.49%-6.09%-8.68%-20.12%+46.20%VRCAVerrica Pharmaceuticals-2.71%-5.29%-14.00%-46.69%-66.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACETAdicet Bio$0.91-1.6%$0.76$0.45▼$1.54$77.32M1.621.88 million shs2.29 million shsGNLXGenelux$5.67+19.4%$3.82$1.99▼$5.89$179.42M-0.22136,522 shs368,482 shsLFCRLifecore Biomedical$6.63-3.5%$7.40$4.33▼$8.85$257.39M0.62215,235 shs270,006 shsVRCAVerrica Pharmaceuticals$4.30-2.7%$5.21$3.82▼$17.38$41.75M1.71598,801 shs190,316 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACETAdicet Bio-1.56%+10.42%+13.75%+21.97%-35.62%GNLXGenelux+19.37%+29.16%+54.50%+65.31%+116.41%LFCRLifecore Biomedical-3.49%-6.09%-8.68%-20.12%+46.20%VRCAVerrica Pharmaceuticals-2.71%-5.29%-14.00%-46.69%-66.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACETAdicet Bio 2.60Moderate Buy$5.67519.85% UpsideGNLXGenelux 2.50Moderate Buy$20.33258.61% UpsideLFCRLifecore Biomedical 2.20Hold$8.0020.66% UpsideVRCAVerrica Pharmaceuticals 2.00Hold$60.001,295.35% UpsideCurrent Analyst Ratings BreakdownLatest GNLX, LFCR, VRCA, and ACET Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ACETAdicet BioGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.0010/8/2025ACETAdicet BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025GNLXGeneluxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025LFCRLifecore BiomedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025VRCAVerrica PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ACETAdicet BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell ➝ Sell (E+)9/27/2025GNLXGeneluxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025LFCRLifecore BiomedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025VRCAVerrica PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/19/2025ACETAdicet BioGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.009/3/2025LFCRLifecore BiomedicalKeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSector Weight(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACETAdicet Bio$24.99M3.05N/AN/A$2.26 per share0.40GNLXGenelux$10K21,415.59N/AN/A$0.76 per share7.46LFCRLifecore Biomedical$128.87M1.93N/AN/A$0.04 per share165.75VRCAVerrica Pharmaceuticals$7.57M5.37N/AN/A($1.07) per share-4.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACETAdicet Bio-$117.12M-$1.31N/AN/AN/AN/A-68.48%-57.84%11/5/2025 (Estimated)GNLXGenelux-$29.87M-$0.86N/AN/AN/AN/A-107.47%-83.14%11/13/2025 (Estimated)LFCRLifecore Biomedical-$38.72M-$1.31N/AN/AN/A-31.70%-846.51%-13.03%10/10/2025 (Estimated)VRCAVerrica Pharmaceuticals-$76.58M-$8.28N/AN/AN/AN/AN/A-115.48%11/3/2025 (Estimated)Latest GNLX, LFCR, VRCA, and ACET EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025ACETAdicet Bio-$0.26N/AN/AN/AN/AN/A11/3/2025Q3 2025VRCAVerrica Pharmaceuticals-$1.14N/AN/AN/A$8.34 millionN/A10/10/2025Q1 2026LFCRLifecore Biomedical-$0.29N/AN/AN/A$26.68 millionN/A8/12/2025Q2 2025VRCAVerrica Pharmaceuticals-$0.70$0.02+$0.72$0.02$4.37 million$12.70 million8/7/2025Q2 2025ACETAdicet Bio-$0.32-$0.34-$0.02-$0.34N/AN/A8/7/2025Q2 2025GNLXGenelux-$0.22-$0.20+$0.02-$0.20N/AN/A8/7/2025Q4 2025LFCRLifecore Biomedical-$0.09-$0.10-$0.01-$0.06$35.36 million$36.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACETAdicet BioN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACETAdicet BioN/A7.487.48GNLXGeneluxN/A4.184.18LFCRLifecore Biomedical113.762.841.77VRCAVerrica PharmaceuticalsN/A1.261.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACETAdicet Bio83.89%GNLXGenelux37.33%LFCRLifecore Biomedical83.36%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipACETAdicet Bio7.80%GNLXGenelux8.80%LFCRLifecore Biomedical31.98%VRCAVerrica Pharmaceuticals54.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACETAdicet Bio9083.25 million76.76 millionOptionableGNLXGenelux1037.77 million34.45 millionNot OptionableLFCRLifecore Biomedical69037.47 million25.48 millionOptionableVRCAVerrica Pharmaceuticals409.45 million4.35 millionOptionableGNLX, LFCR, VRCA, and ACET HeadlinesRecent News About These CompaniesBrokerages Set Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) PT at $60.00October 8 at 3:17 AM | americanbankingnews.comVerrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual MeetingOctober 7 at 4:05 PM | globenewswire.comVerrica Pharmaceuticals stock soars after Japan approves YCANTHSeptember 20, 2025 | ca.investing.comVerrica Pharmaceuticals development partner receives approval for YCANTHSeptember 20, 2025 | msn.comVerrica Pharmaceuticals stock jumps on Japan approves YCANTHSeptember 20, 2025 | msn.comVerrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum ContagiosumSeptember 19, 2025 | globenewswire.comVerrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment ...September 3, 2025 | bakersfield.comBVerrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comVerrica Posts Profit in Fiscal Q2August 14, 2025 | theglobeandmail.comVerrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of EarningsAugust 13, 2025 | finance.yahoo.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | insidermonkey.comVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | finanznachrichten.deVerrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comVerrica Pharmaceuticals Regains Nasdaq ComplianceAugust 12, 2025 | msn.comVerrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat EstimatesAugust 12, 2025 | zacks.comVerrica Pharmaceuticals Reports Second Quarter 2025 Financial ResultsAugust 12, 2025 | globenewswire.com3VRCA : What to Expect from Verrica Pharmaceuticals's EarningsAugust 11, 2025 | benzinga.comVerrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025August 6, 2025 | globenewswire.comVerrica Pharmaceuticals Implements Reverse Stock SplitAugust 1, 2025 | theglobeandmail.comVerrica Pharmaceuticals Inc. (VRCA) Latest Stock News & Headlines ...July 12, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNLX, LFCR, VRCA, and ACET Company DescriptionsAdicet Bio NASDAQ:ACET$0.91 -0.01 (-1.56%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$0.90 -0.01 (-1.55%) As of 05:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.Genelux NASDAQ:GNLX$5.67 +0.92 (+19.37%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$5.50 -0.17 (-2.91%) As of 10/9/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Lifecore Biomedical NASDAQ:LFCR$6.63 -0.24 (-3.49%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$6.54 -0.09 (-1.36%) As of 04:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Verrica Pharmaceuticals NASDAQ:VRCA$4.30 -0.12 (-2.71%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$4.34 +0.04 (+0.95%) As of 10/9/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
